ADPT President and COO Julie Rubinstein Sells $297K of Stock
Key Points
- Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 11,881 shares on October 23, 2026, for approximately $296,842.
- After the trade, Julie Rubinstein holds 377,802 $ADPT shares, down 3.05% from before the trade.
- The recent stock price for ADPT is around $26.27, which is above its closing price of $25.51 on the day of the sale.
- Adaptive Biotechnologies has a market cap of about $4.07 billion and is set to report earnings on November 4, 2026.
Get Adaptive Biotechnologies text alerts
We text you when insiders, Congress, analysts or big funds move on $ADPT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Adaptive Biotechnologies Corporation alert may contain errors. Disclosures
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corporation (ADPT), sold 11,881 shares on October 23, 2026, at a price of $24.98 each. This sale totaled approximately $296,842. Rubinstein's action is part of a planned trading strategy, and it reduced her overall stake by about 3.05%, leaving her with 377,802 shares.
ADPT
Adaptive Biotechnologies Corporation
Other Institutional Activity in Adaptive Biotechnologies
Viking Global Investors, L.P. holds 29,993,708 shares of Adaptive Biotechnologies, valued at about $787.9 million. Shaw D.E. & Co., Inc. increased its position by 2,660,252 shares, bringing its total to 4,625,859 shares worth around $121.5 million. In contrast, Westfield Capital Management Co LP reduced its holdings by 1,168,845 shares, ending with 4,267,645 shares valued at about $112.1 million.
Adaptive Biotechnologies Corporation Stock Up 7.6%
As of October 26, 2026, Adaptive Biotechnologies shares are trading around $26.27, which is about 3% above the closing price of $25.51 on the sale date. The stock is currently above its 50-day moving average of $26.14 and well above its 52-week low of $12. The shares are, however, approximately 14.5% below their 52-week high of $30.74.
Recent Earnings
For the trailing twelve months, Adaptive Biotechnologies reported revenues of approximately $308.1 million, reflecting a year-over-year growth of 21.5%. The company is expected to announce its next earnings on November 4, 2026.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
Julie Rubinstein has been active in selling shares recently, with multiple transactions occurring just before her latest sale. On October 16, 2026, she sold 11,881 shares for about $288,010, followed by similar sales on October 19 and October 20 for $285,738 and $291,473, respectively. Each of these sales was executed under a planned trading strategy.
Analysts Set New Price Targets
On September 22, 2026, BTIG maintained a "Buy" rating on Adaptive Biotechnologies with a price target of $34. On September 29, 2026, Goldman Sachs initiated coverage with a "Buy" rating and a target of $35. Guggenheim also maintained a "Buy" rating with a target of $32 on October 1, 2026. Currently, the consensus recommendation for the stock is a strong buy, with a mean price target of $30.21 based on seven analyst opinions.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a healthcare company based in Seattle, WA. It focuses on developing an immune medicine platform for diagnosing and treating various diseases. The firm utilizes advanced technologies like immunosequencing to decode the adaptive immune system, providing valuable clinical data.
Bottom Line
Investors should keep an eye on Adaptive Biotechnologies as it prepares for its upcoming earnings report on November 4, 2026. With significant insider trading activity and positive analyst ratings, the stock remains a point of interest in the healthcare sector.
Related Filing Alerts
Source: Julie Rubinstein's Form 4 filing on $ADPT (Oct 23, 2026). Written by software, not financial advice. How we make alerts